+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cancer Vaccines Market - Global Forecast 2025-2032

  • PDF Icon

    Report

  • 186 Pages
  • October 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010630
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer vaccines market is emerging as a pivotal arena within oncology, offering pharmaceutical and healthcare leaders new routes to both scientific advancement and commercial growth. Targeted therapies, shifting regulatory frameworks, and dynamic stakeholder engagement continue to accelerate development in this promising sector.

Market Snapshot: Cancer Vaccines Market Size and Growth Drivers

The cancer vaccines market grew from USD 7.11 billion in 2024 to USD 7.78 billion in 2025, and is forecast to reach USD 15.08 billion by 2032, registering a CAGR of 9.84%. Behind this trajectory is the transition of cancer vaccines from experimental status toward mainstream adoption for both preventive and therapeutic applications. Progress in immunology, bioengineering, and regulatory support has enabled engineered vaccines to prime immune responses against tumor cells, reshaping oncology standards. Industry collaboration and partnerships further enhance capacity for clinical translation and commercialization.

Scope & Segmentation Overview

This report offers an in-depth analysis of market dynamics and segmentation factors, enabling a granular view of current and future opportunities in the cancer vaccines landscape.

  • Product Type: Preventive cancer vaccines, therapeutic cancer vaccines
  • Formulations: Cell-based vaccines (including dendritic and tumor cell types), nucleic acid-based vaccines (DNA and RNA formats), peptide/protein-based vaccines, synthetic vaccines, viral vector-based vaccines
  • Administration Pathway: Intramuscular, intravenous
  • Development Phase: Clinical trials, Phase I, Phase II, Phase III
  • Indication: Breast, colorectal, lung, melanoma, prostate cancer
  • End-User: Cancer research institutes, hospitals and clinics, specialty cancer treatment centers
  • Geographical Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
  • Company Analysis: Amgen Inc., Bayer AG, Advaxis Inc., AstraZeneca PLC, BioNTech SE, Bristol Myers Squibb Company, Celldex Therapeutics, CureVac SE, Dynavax Technologies, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK PLC, Helsinn Healthcare, Inovio Pharmaceuticals, Johnson & Johnson, JW CreaGene, Merck & Co., Moderna, Pfizer, Sanofi SA, Sanpower Group, Scorpius Holdings, Serum Institute of India, Sun Pharmaceutical Industries, Vaxine Pty Ltd

Cancer Vaccines Market: Key Takeaways

  • Stakeholders are capitalizing on dual approaches: vaccines that both prevent and treat cancers are being deployed to intercept disease and improve outcomes, reinforcing the market’s comprehensive framework.
  • Market segmentation by modality demonstrates technology diversification, with companies advancing cell-based, nucleic acid, peptide, synthetic, and viral vector platforms to address evolving clinical requirements.
  • Collaborative R&D through academic, industry, and public-private alliances is expediting early-stage discovery, optimizing antigen selection, and advancing personalized cancer vaccine development.
  • Digital tools, biomarker analytics, and adaptive trial designs are accelerating candidate prioritization and regulatory review, enabling faster progression from clinical investigation to commercial readiness.
  • Regional development strategies, such as scale-up of local manufacturing and capacity building in high-incidence geographies, are mitigating supply risks and increasing access to advanced vaccines.

Impact of United States Tariffs on Biologics Supply Chains

New tariffs on imported biologics and adjuvants in the United States are influencing production budgets, sourcing strategies, and project timelines for cancer vaccine manufacturers. Stakeholders are pursuing regional manufacturing partnerships, vendor diversification, and domestic synthesis of key components to preserve operational agility. Facility investment decisions are being revisited, especially as companies evaluate local solutions in cell culture and nucleic acid synthesis to secure continuity of supply and avoid logistical delays. The evolving landscape underscores the importance of resilient supply chain management for sustained cancer vaccine advancement.

Methodology & Data Sources

This report uses a rigorous mixed methodology, integrating primary interviews with experts such as immunologists, oncologists, regulatory advisors, and manufacturing executives. Secondary research draws on academic journals, clinical registries, patent data, and regulatory guidance. Data integrity is ensured through source triangulation and ongoing validation with key stakeholders.

Why This Report Matters

  • Delivers actionable intelligence for investment targeting, regulatory navigation, and technology adoption strategies within the cancer vaccines market.
  • Enables benchmarking against regional and competitor developments to inform go-to-market and localization strategies.

Conclusion

The cancer vaccines market is poised for transformation, driven by technological innovation, flexible development strategies, and adaptive supply chains. Stakeholders equipped with actionable insights and resilient frameworks will be positioned for long-term success in this evolving therapeutic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Rising use of artificial intelligence in identifying novel cancer vaccine targets and optimizing formulations
5.2. Growing investment in neoantigen-based cancer vaccines fueling precision oncology benefits
5.3. Utilization of AI and machine learning for optimizing cancer vaccine design and patient selection
5.4. Development of multi-epitope vaccines designed to elicit broader immune responses against cancer
5.5. Innovations in delivery systems for cancer vaccines increasing efficacy and patient compliance
5.6. Supportive regulatory approvals fueling the commercialization of innovative cancer vaccines
5.7. Expansion of preventive cancer vaccines targeting virus-associated cancers
5.8. Advancements in personalized cancer vaccines leveraging neoantigen targeting enhancing immune response
5.9. Rising collaboration among biotech firms accelerating cancer vaccine research and development
5.10. Expansion of prophylactic cancer vaccines aiming to prevent virus-associated malignancies
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Cancer Vaccines Market, by Product Type
8.1. Preventive Cancer Vaccines
8.2. Therapeutic Cancer Vaccines
9. Cancer Vaccines Market, by Formulations
9.1. Cell-Based Vaccines
9.1.1. Dendritic Cell Vaccines
9.1.2. Tumor Cell Vaccines
9.2. Nucleic Acid-Based Vaccines
9.2.1. DNA Vaccines
9.2.2. RNA Vaccines
9.3. Peptide/Protein-Based Vaccines
9.4. Synthetic Vaccines
9.5. Viral Vector-Based Vaccines
10. Cancer Vaccines Market, by Administration Pathway
10.1. Intramuscular
10.2. Intravenous
11. Cancer Vaccines Market, by Development Phase
11.1. Clinical Trials
11.2. Phase I
11.3. Phase II
11.4. Phase III
12. Cancer Vaccines Market, by Indication
12.1. Breast Cancer
12.2. Colorectal Cancer
12.3. Lung Cancer
12.4. Melanoma
12.5. Prostate Cancer
13. Cancer Vaccines Market, by End-User
13.1. Cancer Research Institutes
13.2. Hospitals & Clinics
13.3. Specialty Cancer Treatment Centers
14. Cancer Vaccines Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Cancer Vaccines Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Cancer Vaccines Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Amgen Inc.
17.3.2. Bayer AG
17.3.3. Advaxis Inc.
17.3.4. AstraZeneca PLC
17.3.5. BioNTech SE
17.3.6. Bristol Myers Squibb Company
17.3.7. Celldex Therapeutics, Inc.
17.3.8. CureVac SE
17.3.9. Dynavax Technologies Corporation
17.3.10. Eli Lilly and Company
17.3.11. F. Hoffmann-La Roche AG
17.3.12. GSK PLC
17.3.13. Helsinn Healthcare SA
17.3.14. Inovio Pharmaceuticals, Inc.
17.3.15. Johnson & Johnson Services, Inc
17.3.16. JW CreaGene
17.3.17. Merck & Co., Inc.
17.3.18. Moderna, Inc.
17.3.19. Pfizer Inc.
17.3.20. Sanofi SA
17.3.21. Sanpower Group Co., Ltd.
17.3.22. Scorpius Holdings, Inc.
17.3.23. Serum Institute of India Pvt. Ltd.
17.3.24. Sun Pharmaceutical Industries Ltd.
17.3.25. Vaxine Pty Ltd
List of Tables
List of Figures

Samples

Loading
LOADING...

Companies Mentioned

The key companies profiled in this Cancer Vaccines market report include:
  • Amgen Inc.
  • Bayer AG
  • Advaxis Inc.
  • AstraZeneca PLC
  • BioNTech SE
  • Bristol Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • CureVac SE
  • Dynavax Technologies Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GSK PLC
  • Helsinn Healthcare SA
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc
  • JW CreaGene
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sanpower Group Co., Ltd.
  • Scorpius Holdings, Inc.
  • Serum Institute of India Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Vaxine Pty Ltd

Table Information